

Journal of Visualized Experiments

A Protocol for Enhanced Rabies Surveillance Using a Direct Rapid Immunohistochemical Test

--Manuscript Draft--

Article Type:	Invited Methods Collection - JoVE Produced Video
Manuscript Number:	JoVE59416R3
Full Title:	A Protocol for Enhanced Rabies Surveillance Using a Direct Rapid Immunohistochemical Test
Keywords:	diagnosis, direct rapid immunohistochemical test, fluorescent antibody test, lyssavirus, rabies, zoonosis
Corresponding Author:	Erin M Patrick US Department of Agriculture Knoxville, TN UNITED STATES
Corresponding Author's Institution:	US Department of Agriculture
Corresponding Author E-Mail:	erin.patrick@aphis.usda.gov
Order of Authors:	Erin M Patrick Brian M Bjorklund Jordona D Kirby Kathleen M Nelson Richard B Chipman Charles E Rupprecht
Additional Information:	
Question	Response
Please indicate whether this article will be Standard Access or Open Access.	Open Access (US\$4,200)
Please indicate the city, state/province, and country where this article will be filmed . Please do not use abbreviations.	Sutton, MA

TITLE:

Enhanced Rabies Surveillance Using a Direct Rapid Immunohistochemical Test

AUTHORS AND AFFILIATIONS:

Erin M Patrick¹, Brian M Bjorklund², Jordona D Kirby³, Kathleen M Nelson⁴, Richard B Chipman⁴, Charles E Rupprecht⁵

¹United States Department of Agriculture (USDA), Animal and Plant Health Inspection Service (APHIS), Wildlife Services, Knoxville, TN, USA

²USDA, APHIS, Wildlife Services, Sutton, MA, USA

³USDA, APHIS, Wildlife Services, Milton, FL, USA

⁴USDA, APHIS, Wildlife Services, Concord, NH, USA

⁵Lyssa LLC, Cumming, GA, USA

Corresponding Author:

Erin M. Patrick

Erin.Patrick@usda.gov

Email addresses of Co-authors:

Brian Bjorklund (Brian.Bjorklund@usda.gov)

Jordona Kirby (Jordona.D.Kirby@usda.gov)

Kathleen Nelson (Kathleen.M.Nelson@usda.gov)

Richard Chipman (Richard.B.Chipman@usda.gov)

Charles Rupprecht (charleserupprechtii@gmail.com)

KEYWORDS:

diagnosis, direct rapid immunohistochemical test, fluorescent antibody test, lyssavirus, rabies, zoonosis

SUMMARY:

The direct rapid immunohistochemical test (DRIT) offers a World Organization for Animal Health and World Health Organization (OIE/WHO) recognized alternative to the direct fluorescent antibody (DFA) test for rabies diagnosis. This test allows for field-based applications that can be performed in approximately 1 h upon brain impressions using light microscopy.

ABSTRACT:

Laboratory-based surveillance is integral for rabies prevention, control and management efforts. While the DFA is the gold standard for rabies diagnosis, there is a need to validate additional diagnostic techniques to improve rabies surveillance, particularly in developing countries. Here, we present a standard protocol for the DRIT as an alternative, laboratory or field-based testing option that uses light microscopy as compared to the DFA. Touch impressions of brain tissue collected from suspect animals are fixed in 10% buffered formalin. The DRIT uses rabies virus-specific monoclonal or polyclonal antibodies (conjugated to biotin), a streptavidin-peroxidase enzyme, and a chromogen reporter (such as acetyl 3-amino-9-ethylcarbazole) to detect viral inclusions within infected tissue. In approximately 1 h, a brain tissue sample can be tested and

interpreted by the DRIT. Evaluation of suspect animal brains tested from a variety of species in North America, Asia, Africa, and Europe have illustrated high sensitivity and specificity by the DRIT approaching 100% with results compared to DFA. Since 2005, the United States Department of Agriculture's Wildlife Services (USDA WS) program has conducted large-scale enhanced rabies surveillance efforts using the DRIT to test >94,000 samples collected from wildlife in strategic rabies management areas. The DRIT provides a powerful, economical tool for rabies diagnosis that can be used by laboratorians and field biologists to improve current rabies surveillance, prevention and control programs globally.

INTRODUCTION:

While the DFA is the most widely used test for routine rabies diagnosis¹, the cost of purchasing and maintaining a fluorescent microscope can be limiting to developing nations²⁻⁴ and for broad, large-scale enhanced rabies surveillance programs^{3,4}. In addition, the DFA requires the ability to refrigerate samples during fixation and to incubate samples above ambient temperature during the antibody-antigen reactions, which can be a significant hurdle in countries without suitable infrastructure. Due in part to the limitations associated with modern DFA testing, the global impact of rabies has long been underestimated⁵.

In this regard, there is a need to validate additional diagnostic techniques to improve rabies surveillance globally, particularly in developing countries. The DRIT protocol presented here offers a laboratory or field-based testing alternative to the DFA that uses light microscopy and does not require refrigeration or laboratory incubation during the test⁶. The DRIT and DFA are similar in that both techniques use touch impressions of brain samples collected from potentially rabid animals. However, the first step of the DRIT uses formalin as an historical fixative for samples, which inactivates rabies virus. This provides a substantial biosafety improvement over the acetone used to fix samples in the DFA protocol³, which is important not only in the laboratory but perhaps even more so in field-based or decentralized lab environments. To date, the DRIT shows sensitivity and specificity equal to the DFA^{2,7-9}.

Since 2005, the USDA WS program has conducted large-scale enhanced rabies surveillance efforts in North America using the DRIT as part of a comprehensive wildlife rabies management program¹⁰. Enhanced rabies surveillance is used as a complement to exposure-based public health surveillance and tests primarily wildlife meso-carnivore species, including raccoons (*Procyon lotor*), striped skunks (*Mephitis mephitis*), gray foxes (*Urocyon cinereoargenteus*), red foxes (*Vulpes vulpes*), and coyotes (*Canis latrans*) that have not been involved in a human or domestic animal exposure. Animal carcasses used in testing were submitted to USDA WS through enhanced rabies surveillance efforts and comprised rabies vector species that are: ill or strange acting; found dead, road-killed, or a nuisance; and are not associated with a human or domestic animal exposure. The DRIT provides a rabies diagnostic test that can be employed by trained field biologists with little or no laboratory experience to improve rabies surveillance and reduce the financial burden and workload of public health diagnostic laboratories¹⁰. The basic DRIT training for USDA WS field employees typically takes 1.5 to 2 days, which includes approximately 4 h of classroom instruction covering fundamental principles of biosafety, methods for sample collection and the DRIT processes as well as >8 h of laboratory time conducting the test. Training

opportunities have been available to USDA WS and program cooperators through the Centers for Disease Control and Prevention (CDC), LYSSA LLC, and The Wistar Institute.

Within strategic management areas, USDA WS has tested over 94,000 wildlife samples using the DRIT and has detected more than 1,850 rabid samples that would have likely gone undetected relying only upon exposure based public health testing of suspect animals. Enhanced rabies surveillance data provided by DRIT results are critical to providing a more complete temporal and spatial representation of rabies on the landscape in support of oral rabies vaccination programs for wildlife throughout the USA^{10,11}. Similarly, Provincial wildlife agencies in Canada have incorporated DRIT into large scale wildlife rabies surveillance efforts in tandem with their public health programs with success⁸. Both USDA WS and Canadian DRIT surveillance programs have used national reference laboratories to confirm rabies by DFA and to perform viral variant typing as appropriate⁸. Moreover, USDA WS field biologists send 10% of negative specimens for DFA confirmation to reference laboratories and since 2008, have participated in biannual DRIT proficiency testing provided by the Wisconsin State Laboratory of Hygiene, as part of standard quality assurance measures.

The goal of this method is to offer an alternative approach for rabies diagnostic testing that can be done in decentralized laboratories, in the field, or in areas without routine access to electron microscopy.

PROTOCOL:

Each person conducting rabies diagnostic testing should receive a standard pre-exposure rabies vaccination series and undergo regular serological antibody evaluation, with booster immunizations as needed. Unimmunized individuals should not enter laboratories or areas where such work is conducted. All manipulation of tissues and slides should be conducted to not aerosolize liquids or produce airborne particles. Fume hoods are not required but when feasible they can provide extra protection from odors, ectoparasites, and bone fragments. Minimum personal protective equipment, including gloves and eye protection, should be worn at all times during sample collection and testing.

1. Brainstem collection

1.1. Collect brainstem samples either immediately upon carcass collection or ensure that carcasses are placed in freezers for storage until later testing. If animal carcasses are frozen, thaw at ambient temperature prior to brainstem collection for ease of collection. Under some circumstances, samples are collected directly from a frozen animal.

1.2. For animals that are freshly collected or have been thawed to ambient temperature, position the animal supine on a flat surface with the cervical spine slightly rotated towards the examiner. Palpate to identify the atlanto-occipital joint on the lateral aspect of the cervical spine.

1.2.1. For carcasses that are still completely frozen, position the animal supine as described above, if practical. Use saws, knives, bone shears or similar equipment to completely separate

the head from the body. Note – all equipment used that is not one-time use should be cleaned thoroughly between samples.

1.3. Using a scalpel blade, make an incision at the level of the atlanto-occipital joint at the ventral aspect, cutting through all layers of muscle and soft tissue, including the trachea and esophagus. Continue until approximating anterior aspect of cervical spine vertebrae. For frozen tissue, use a scalpel blade to remove any remaining layers of muscle and soft tissue to expose the foramen magnum.

1.4. Move the head of the animal into end-range extension until the brainstem is visible. Use a scalpel blade to remove all visible brainstem/central nervous system (CNS) tissue for sampling. For a frozen sample, use a scalpel blade to remove as much of the frozen brainstem/CNS tissue as possible from inside the skull.

1.5. Place the brainstem samples in an unbreakable container (i.e., metal ointment tin, cryovial, etc.) and label accordingly.

1.6. Ensure that the brainstem samples are tested immediately after collection via the DRIT test, refrigerated (4 °C) for up to 24 h before testing, or frozen (-20 °C) until time of testing if testing will take place more than 24 h after sample collection.

2. Preparation of materials for DRIT

2.1. Setting up of 10 slide staining dishes (Figure 1)

NOTE: Staining dishes are deep enough to allow for complete immersion of slide (diameter 96 mm, height 72 mm, depth 42mm, volume 250 mL).⁶

2.1.1. Fill dish 1 with 10% phosphate buffered formalin. Replace formalin after 2 test runs or weekly.

2.1.2. Fill dishes 2, 4, and 5 with phosphate buffered saline with 1% tween-80 (TPBS). Replace with fresh TPBS before each test.

2.1.3. Fill dish 3 with 3% hydrogen peroxide. Replace hydrogen peroxide before each test.

2.1.4. Fill dishes 6, 8, 9, and 10 with distilled or deionized water. Replace water before each test.

2.1.5. Fill dish 7 with Gills hematoxylin formulation #2 diluted in a 1:1 ratio in distilled water⁶. Replace hematoxylin after 2 test runs or weekly.

NOTE: According to the original DRIT protocol developed by the CDC¹², a 1:2 ratio of Gills hematoxylin to water may be used if counterstaining is too dark.

2.2. Preparation of amino-ethylcarbazole (AEC) stock solution

2.2.1. Using a glass pipette, place 5 mL of N,N-dimethylformamide in a glass container.

2.2.2. Add one 20 mg tablet of 3-amino-9-ethylcarbazole and shake until completely dissolved. Label the jar with "AEC stock" and the date the stock was made.

NOTE: The AEC stock solution can be stored under refrigeration (4 °C) and used for 1-2 months.

2.3. Preparation of AEC working dilution

2.3.1. Add 7 mL of acetate buffer to a 15 mL centrifuge tube.

2.3.2. Using a glass pipette, add 0.5 mL of the AEC stock solution to the centrifuge tube.

2.3.3. Add 0.075 mL of 3% hydrogen peroxide to the tube.

2.3.4. Filter the solution with a 10 mL syringe using a 0.45 µm syringe filter.

NOTE: The AEC working dilution should be created just prior to each DRIT test as it is only stable for 2-3 h.

3. Direct rapid immunohistochemistry test

3.1. Label glass microscope slides with a unique number for each specimen using a smear-proof, waterproof, permanent ink marker.

3.1.1. Using a scalpel blade, remove the brainstem from the container and place on paper towel. Gently blot away any excess of fluid, blood, or fur with a second paper towel to reveal just the brainstem tissue¹³. If needed, section the brainstem tissue to reveal a cross section.

3.1.2. Very gently touch the microscope slide to the cross section of the brainstem tissue. Touch the slide to the brainstem at several points without lateral movement to allow multiple areas of brainstem to be transferred to slide¹³. Ensure that only 1 or 2 layers of cells are transferred from the brain tissue to the slide with a gentle touch. No mounting agent is needed to affix the brainstem tissue to the slides. Include both a positive and negative control in each DRIT run.

3.2. Let the slides air-dry for approximately 5 min at room temperature.

3.3. Immerse the slides in 10% buffered formalin for 10 min (dish 1).

3.4. Remove the slides from formalin and dip-rinse in a solution of TPBS (dish 2).

3.5. Immerse the slides in 3% hydrogen peroxide for 10 min (dish 3).

3.6. Remove the slides from the hydrogen peroxide and dip-rinse in fresh TPBS (dish 4). After removing excess hydrogen peroxide, place the slides in fresh TPBS (dish 5) and work with one slide at a time while the other slides stay immersed in TPBS.

3.7. Take the slides from TPBS (dish 5) one at a time, shake off and blot excess buffer, and place on a moistened paper towel on lab bench, as the basis of a 'humidity chamber'. Using a pipette, drop enough primary anti-rabies virus antibody on each slide to cover the CNS tissue. Incubate the slides for 10 min in the humidity chamber (i.e., covering slides with well plates or other simple cover while they are laying on the moistened paper towel) at room temperature (**Figure 2**).

3.8. Remove the slides from the humidity chamber, shake and blot off excess conjugate, and dip-rinse the slides in TPBS (reuse the same TPBS in dish 5).

3.9. Working with one slide at a time, while others stay immersed in TPBS – use a pipette to drop enough streptavidin-peroxidase complex to cover the CNS tissue. Incubate in the humidity chamber for 10 min at room temperature.

3.10. Remove the slides from the humidity chamber, shake and blot off excess complex, and dip-rinse the slides in TPBS (dish 5).

3.11. Working with one slide at a time, shake off and blot excess buffer, while others stay immersed in TPBS – use a pipette to drop enough AEC (preparation is explained above and should be done immediately prior to use) to cover the CNS tissue. Incubate in the humidity chamber for 10 min at room temperature.

3.12. Dip-rinse the slides in distilled water (dish 6).

3.13. Place the slides in counterstain of Gills Hematoxylin (diluted 1:1 with distilled water) for 2 min (dish 7).

3.14. Immediately dip-rinse all slides in distilled water (dish 8). Repeat twice with fresh water each time (dishes 9 and 10).

3.15. Working with one slide at a time, while others stay immersed in distilled water (dish 10) – shake and blot off excess water and use a water-soluble mounting medium to affix a cover slip.

3.16. Use a light microscope with a 20X objective to view the slides and a 40X objective if closer inspection is needed.

REPRESENTATIVE RESULTS:

Positive results from the DRIT show red intracytoplasmic viral inclusions that can vary in shape and size (**Figure 3**) within the cytoplasm of bluish cell bodies. The inclusions appear smooth with

very bright margins and a less intensively stained central area. Intensity and antigen distribution are recorded when inclusions are detected. Intensity is graded from +4 to +1. The positive control slide should have an intense, glaring magenta brilliance which is referred to as a +4 intensity. A slight loss of color can occur especially when sample handling has not been optimal (i.e., sample tissue has decomposed slightly) and these should be graded as +3. Noticeably dull stain is graded as a +2 to +1, is not considered diagnostic for rabies virus infection and is labeled as indeterminate.

Additionally, antigen distribution is graded from +4 to +1 with +4 representing antigen distribution comprised of an abundance of large and small inclusions varying in size and shape, and present in every field (or almost every field) of view within the CNS tissue touch impression. The positive control typically has a +4 antigen distribution. An antigen distribution of +3 would be assigned when there are inclusions in a variety of sizes in most but not all of the fields of view. If inclusions are found in 10% - 50% of the microscope fields, a +2 antigen distribution is assigned. When inclusions are found in <10% of the microscope fields, a +1 antigen distribution is assigned.

Most CNS tissue with rabies virus present exhibit typical viral inclusions graded as +3 or +4 intensity and antigen distribution. If results indicate a +2 or +1 intensity or a +2 or +1 antigen distribution, the sample is declared an “indeterminate” and repeat testing is warranted. If the same sample has a repeat indeterminate test result, the sample should be sent to a reference laboratory for DFA or related confirmatory testing.

A test sample using the DRIT is considered negative for rabies virus antigens after the slide containing the CNS tissue has been scanned at a magnification of 200X or greater and no typical virus inclusions are detected (**Figure 4**). Negative samples exhibit bluish cell bodies with little or no nonspecific staining.

FIGURE AND TABLE LEGENDS:

Figure 1: Setup of 10 slide staining dishes with reagents for testing. The dishes are labeled with reagent name in the order needed to follow the protocol.

Figure 2: Simple humidity chamber created with a wet paper towel and cell culture plates. A simple humidity chamber using a wet paper towel and cell culture plates allows for field-based application.

Figure 3: Representative slides of rabies positive viral inclusions with +4 intensity and +4 antigen distribution. A and B show positive rabies viral inclusions at 200X magnification. C and D show positive rabies viral inclusions at 400X magnification. Scale bars indicate 5 µm.

Figure 4: Representative slides of negative samples with no rabies viral inclusions. A and B show samples negative for rabies viral inclusions at 200X magnification. C and D show samples negative for rabies viral inclusions at 400X magnification. Scale bars indicate 5 µm.

Figure 5: Representative photographs of DRIT testing facilities used by USDA WS. (A) Mobile

testing facility in an enclosed trailer for transport. (B) Recreational vehicle retrofitted for DRIT testing. (C) DRIT testing facility in conjunction with university laboratory.

DISCUSSION:

The DRIT is a flexible method suited for field-based surveillance for detecting the presence of rabies virus that can be used in decentralized laboratory areas. While it is possible to conduct the entire test in a field-based setting such as on the tailgate of a truck, it is ideal to have a small, indoor space dedicated for DRIT due to chemical, equipment and supply storage issues. Additionally, adherence to all applicable federal, state, and local laws, and regulations for chemical use and disposal must be considered. Currently, USDA WS has 15 DRIT facilities to test samples from 17 states. The USDA WS DRIT facilities are established in conjunction with university and state public health laboratories, in designated rooms within larger facilities and in enclosed trailers that have been retrofitted and converted to serve as mobile testing units in the event of an emergency outbreak response where enhanced rabies surveillance testing with immediate turnaround time is critical (**Figure 5**).

While the test has been successful using brainstem material of variable quality, fresh brainstem tissue with no tissue decomposition is optimal. As decomposition, desiccation, or liquefaction occurs, sample quality decreases and the test may detect more nonspecific staining which can confuse results. This observation is similar between DFA and DRIT². Brainstem/CNS should be collected as soon as possible and then stored frozen (-20 °C) until testing.

Typically, most USDA WS facilities process from 12 to 24 slides at once during a DRIT session, including one positive control and one negative control that have been confirmed via DFA. Positive and negative controls provide a reference point for each DRIT run to ensure the test was successful and to confirm if interpretative questions arise on the test slides. If a sample is not determined to have a clear positive or negative outcome, it is labeled as an indeterminate and tested a second time by DRIT. If this sample is not a clear positive or negative after two DRIT tests, it is sent to a reference laboratory for DFA or related testing.

As with any diagnostic test, 'trouble shooting' is useful with unexpected findings. For example, if a DRIT run is unsuccessful (i.e., the positive control does not exhibit +3 or +4 staining intensity and antigen distribution), ensure all chemicals and reagents have not expired. We have found using a newly opened bottle of hydrogen peroxide at a minimum of once per week is helpful to help prevent non-specific staining through oxidation of the brain tissue. Additionally, we recommend replacing acetate buffer at least once each year at a minimum, regardless of the labeled expiration date.

There are a number of advantages of the DRIT over DFA including lower costs, ability to perform the test outside of a centralized laboratory, need for only light microscopy instead of a fluorescent microscope, and the relatively straightforward training process for people administering and reading the test²⁻⁴. These advantages, coupled with sensitivity and specificity of the DRIT that are comparable to DFA^{2,7-9} have already proven that the test serves as an important tool in broad scale enhanced rabies surveillance programs^{8,10} in North America.

353 Additionally, the DRIT has potential to allow for increased surveillance and more prompt testing
354 in developing nations or other areas with limited resources, especially after recent OIE/WHO
355 guidance as a recommended test.

357 **ACKNOWLEDGMENTS:**

358 We acknowledge all USDA Wildlife Services staff who currently or have previously collected
359 enhanced rabies surveillance samples and have conducted the DRIT for rabies diagnosis.
360 Likewise, we acknowledge the many cooperators who assist us with Enhanced Rabies
361 Surveillance collection. We also thank the Centers for Disease Control and Prevention and The
362 Wistar Institute for access to critical reagents required to conduct the DRIT and for providing
363 training opportunities. In addition, we appreciate the confirmatory diagnostics and technical
364 assistance provided by the Centers for Disease Control and Prevention and by the Wadsworth
365 Center with the New York State Department of Health. Use of any commercial products is for
366 comparison purposes only and does not constitute endorsement.

368 **DISCLOSURES:**

369 The authors have nothing to disclose.

371 **REFERENCES:**

- 372 1 Dean, D. J., Abelseth, M. K. & Atanasiu, P. in *Laboratory techniques in rabies* Vol. 23 eds
373 Meslin F.X., Kaplan M.M., & Koprowski, H. 88-89 (World Health Organization, 1996).
- 374 2 Durr, S. et al. Rabies diagnosis for developing countries. *PLOS Neglected Tropical Diseases*.
375 **2** (3), e206, (2008).
- 376 3 Rupprecht, C. et al. Progress in the development of a direct rapid immunohistochemical
377 test for diagnosing rabies. (2014).
- 378 4 Rupprecht, C. E. et al. Additional Progress in the Development and Application of a Direct,
379 Rapid Immunohistochemical Test for Rabies Diagnosis. *Journal of Veterinary Science*. **5**
380 (2), (2018).
- 381 5 Coleman, P. G., Fevre, E. M. & Cleaveland, S. Estimating the public health impact of rabies.
382 *Emerging Infectious Diseases*. **10** (1), 140-142, (2004).
- 383 6 Standard Operating Procedure for the Direct Rapid Immunohistochemistry Test (DRIT) for
384 the detection of rabies virus antigens. (Centers for Disease Control and Prevention, 2016).
- 385 7 Lembo, T. et al. Evaluation of a direct, rapid immunohistochemical test for rabies
386 diagnosis. *Emerging Infectious Diseases*. **12** (2), 310-313, (2006).
- 387 8 Middel, K., Fehlner-Gardiner, C., Pulham, N. & Buchanan, T. Incorporating Direct Rapid
388 Immunohistochemical Testing into Large-Scale Wildlife Rabies Surveillance. *Tropical*
389 *Medicine and Infectious Disease*. **2** (3), 21, (2017).
- 390 9 Coetzer, A., Sabeta, C. T., Markotter, W., Rupprecht, C. E. & Nel, L. H. Comparison of
391 biotinylated monoclonal and polyclonal antibodies in an evaluation of a direct rapid
392 immunohistochemical test for the routine diagnosis of rabies in southern Africa. *PLOS*
393 *Neglected Tropical Diseases*. **8** (9), e3189, (2014).
- 394 10 Kirby, J. et al. Enhanced Rabies Surveillance to Support Effective Oral Rabies Vaccination
395 of Raccoons in the Eastern United States. *Tropical Medicine and Infectious Disease*. **2** (3),
396 34, (2017).

397 11 Slate, D. et al. Oral rabies vaccination in north america: opportunities, complexities, and
398 challenges. *PLOS Neglected Tropical Diseases*. **3** (12), e549, (2009).
399 12 *Direct Rapid Immunohistochemistry Test (DRIT) protocols,*
400 [\(<https://rabiessurveillanceblueprint.org/Direct-Rapid-Immunohistochemistry?lang=fr>](https://rabiessurveillanceblueprint.org/Direct-Rapid-Immunohistochemistry?lang=fr) (
401 13 Khalid, A. & Haque, A. *Touch Impression Cytology Versus Frozen Section as Intraoperative*
402 *Consultation Diagnosis*. Vol. 2 (2004).
403
404

Figure 1

[Click here to access/download;Figure;Figure1.pdf](#)



Figure 2

[Click here to access/download;Figure;Figure2.pdf](#)



Figure 3

[Click here to access/download:Figure:Figure3.pdf](#)







Figure 4

[Click here to access/download;Figure;Figure4.pdf](#) 







Figure 5

[Click here to access/download;Figure;Figure5.pdf](#)



Name of Material/ Equipment

3-Amino-9-Ethylcarbazole (AEC tablets; 50 count)
Acetate Buffer, 0.1M, 5.2 pH, 32oz
Ag Tek MiniScalpel, PN110, Non-sterile #10, 40 per package
BD Luer-Lok Disposable Syringe without needle, 10cc
Binocular Light Microscope with Seidentopf Head or equivalent
Blue Rectangular UN-rated Disposal Container, 5G
Corning Square and Rectangular Cover Glass, 24x60
Corning Universal Fit Pipet Tips: Racked, Nonsterile (1-200ul)
Falcon 15mL Conical Centrifuge Tubes, polypropylene
Falcon 96-Well Assay Plates (Tissue culture plate lids)
Fisher Brand 25mm Syringe Filter, Nylon, 0.45um, Sterile
Fisher Chemical Gill Method Hematoxylin Stain (Gill-2), 4L
Fisherbrand Sharps-A-Gator Point-of-Use Sharps Containers, 5qt
Fluoro-Gel with Tris Buffer (Gel/Mount Media), 20mL
Formalin, Buffered, 10%, 4L
Gilson Pipetman P200 Pipet, 50-200uL
Hy-Clone Phosphate Buffered Saline, 1X Solution, 1L (PBS)
Hydrogen Peroxide, 3%
Lens Microscope Objective 20X and 40X
Lysol IC Quarternary Disinfecting Cleaner, 1G
Miltex brand Disposable Scalpel Size 22 (alternative size to MiniScalpel)
N,N-Dimethylformamide, Amber Glass Packaging, 500mL
Peroxidase Labeled Streptavidin, 50mL
Phosphate Buffered Saline Powder (alternative to Fisher liquid PBS)
Primary antibody: Polyclonal anti-nucleoprotein or cocktail of anti-lyssavirus biotinylated antibodies
PYREX Disposable Serological Pipets, Glass, Sterile, Plugged, Corning, 1.0mL
PYREX Disposable Serological Pipets, Glass, Sterile, Plugged, Corning, 10.0mL
PYREX Disposable Serological Pipets, Glass, Sterile, Plugged, Corning, 5.0mL
Richard-Allan Scientific Gills Hematoxylin Stain No. 2, 1PT (alternative to above)
Slide Holders, 24-place
Specimen Tin Boxes, 1/2oz
Taylor 2-Event Digital Timer/Clock
Tissue-Tek Slide Staining Kit
TWEEN 80, Polyethylene glycol, 500mL
VWR FLIP Pipette Filler (0.05-100mL)
VWR Soft Nitrile Examination Gloves, L (100 per box)
Water, Deionized (20L)
Wheaton Clear Glass Sample Vials, 8mL
White Coated, Double Well Pattern Microscope Slides, 14mm
White Rectangular UN-rate Disposal Container, 5G

Company

Sigma Aldrich (<https://www.sigmaaldrich.com/>)

Poly Scientific R&D Corp. (<https://www.polyrnd.com/>)

Patterson Veterinary (<https://www.pattersonvet.com/>)

Fisher Scientific (part of Thermo Fisher Scientific <https://www.fishersci.com/us/en/home.html>)

Multiple Vendors

Berlin Packaging (<https://www.berlinpackaging.com/>)

Fisher Scientific (part of Thermo Fisher Scientific <https://www.fishersci.com/us/en/home.html>)

Fisher Scientific (part of Thermo Fisher Scientific <https://www.fishersci.com/us/en/home.html>)

Fisher Scientific (part of Thermo Fisher Scientific <https://www.fishersci.com/us/en/home.html>)

Fisher Scientific (part of Thermo Fisher Scientific <https://www.fishersci.com/us/en/home.html>)

Fisher Scientific (part of Thermo Fisher Scientific <https://www.fishersci.com/us/en/home.html>)

Fisher Scientific (part of Thermo Fisher Scientific <https://www.fishersci.com/us/en/home.html>)

Fisher Scientific (part of Thermo Fisher Scientific <https://www.fishersci.com/us/en/home.html>)

VWR, part of Avantor (<https://vwr.com>)

Fisher Scientific (part of Thermo Fisher Scientific <https://www.fishersci.com/us/en/home.html>)

Daigger Scientific (<https://www.daigger.com>)

Fisher Scientific (part of Thermo Fisher Scientific <https://www.fishersci.com/us/en/home.html>)

Multiple Vendors

Multiple Vendors

Daigger Scientific (<https://www.daigger.com>)

AMD Next (www.amdnext.com)

Fisher Scientific (part of Thermo Fisher Scientific <https://www.fishersci.com/us/en/home.html>)

SeraCare (<https://www.seracare.com/>)

Sigma Aldrich (<https://www.sigmaaldrich.com/>)

VWR, part of Avantor (<https://vwr.com>)

VWR, part of Avantor (<https://vwr.com>)

VWR, part of Avantor (<https://vwr.com>)

Fisher Scientific (part of Thermo Fisher Scientific <https://www.fishersci.com/us/en/home.html>)

VWR, part of Avantor (<https://vwr.com>)

VWR, part of Avantor (<https://vwr.com>)

Multiple Vendors

VWR, part of Avantor (<https://vwr.com>)

Sigma Aldrich (<https://www.sigmaaldrich.com/>)

VWR, part of Avantor (<https://vwr.com>)

VWR, part of Avantor (<https://vwr.com>)

VWR, part of Avantor (<https://vwr.com>)

Fisher Scientific (part of Thermo Fisher Scientific <https://www.fishersci.com/us/en/home.html>)

Tekdon Incorporated (<https://www.tekdon.com/coated-microscope-slides.html>)

Berlin Packaging (<https://www.berlinpackaging.com/>)

Catalog Number
A6926
s140
PN110
14-823-2A
1147T01BLU
12-553-465
07-200-300
14-959-70C
08-772-5
09-719D
CS401-1D
14-827-122
102092-122
SF100-4
EF9930E
SH30256LS
EF8481
999112314
D119-500
5550-0001
P3813
7078D-1
7078D-10
7078D-5
22-050-201
25608-868
101412-452
25608-902
P1754
53497-055
89038-272
10806-022
06-408C
2-140
1147T01WHT

Comments/Description

Supplemental equipment for sample touch impressions; Also available through Clipper Distributing (<http://www.clipperdistributing.com>)
BD Manufacturer Number 309604

Supplemental equipment for chemical waste storage/disposal (Gill hematoxylin and AEC solution)
Corning Manufacturer Number 2975246
Corning Manufacturer Number 4863
Corning Manufacturer Number 352097
Corning Manufacturer Number 353910

Supplemental equipment for proper BSL-2 Laboratory Set-Up
Fluoro-Gel Substitute for BioMeda™ Gel-Mount, Electron Microscopy Sciences
Available each or in case of 4

Alternative dry powder product can be used
Any commercially available source, such as pharmacy or store brands, etc.

Supplemental materials for proper BSL-2 Laboratory disinfection
Supplemental equipment for sample touch impressions; Alternative size to Ag Tek MiniScalpel

KPL Immunoassay and Kits Reference Number 71-00-38
Must be prepared in 1L distilled water; Available in quantities of 1, 10 and 50 packs
Store at 4 degrees C
VWR Manufacturer Number 89091-220
VWR Manufacturer Number 89091-106
VWR Manufacturer Number 89091-484
Thermo Scientific Manufacturer Number 72504
Sakura®Finetek Supplier Number 4465; Available through multiple vendors
Supplemental equipment for storage of brain tissue samples
Supplemental equipment
Sakura®Finetek Supplier Number 4551; Available through multiple vendors
Also available in 25mL, 1L and 1G volumes

Supplemental equipment for proper PPE

DWK Life Sciences Manufacturer Number 224884

Supplemental equipment for chemical waste storage/disposal (Formalin)

://www.clipperdist.net/)

ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article:	A Protocol for Enhanced Rabies Surveillance Using a Direct Rapid Immunohistochemical Test
Author(s):	Erin M Patrick, Brian M Bjorklund, Jordana D Kirby, Kathleen M Nelson, Richard B Chipman, Charles E Rupprecht

Item 1: The Author elects to have the Materials be made available (as described at <http://www.jove.com/publish>) via:

☐

Standard Access

☒

Open Access

Item 2: Please select one of the following items:

☐

The Author is **NOT** a United States government employee.

☒

The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.

☐

The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: **"Agreement"** means this Article and Video License Agreement; **"Article"** means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; **"Author"** means the author who is a signatory to this Agreement; **"Collective Work"** means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; **"CRC License"** means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; **"Derivative Work"** means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; **"Institution"** means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; **"JoVE"** means MyJoVE Corporation, a Massachusetts corporation and the publisher of The Journal of Visualized Experiments; **"Materials"** means the Article and / or the Video; **"Parties"** means the Author and JoVE; **"Video"** means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion

of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to **Sections 4** and **7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the "Open Access" box has been checked in **Item 1** above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

ARTICLE AND VIDEO LICENSE AGREEMENT

4. **Retention of Rights in Article.** Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. **Grant of Rights in Video – Standard Access.** This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. **Grant of Rights in Video – Open Access.** This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this **Section 6** is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. **Government Employees.** If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum

rights permitted under such statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. **Protection of the Work.** The Author(s) authorize JoVE to take steps in the Author(s) name and on their behalf if JoVE believes some third party could be infringing or might infringe the copyright of either the Author's Article and/or Video.

9. **Likeness, Privacy, Personality.** The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

10. **Author Warranties.** The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

11. **JoVE Discretion.** If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole

ARTICLE AND VIDEO LICENSE AGREEMENT

discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

12. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to


the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

13. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

14. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement is required per submission.

CORRESPONDING AUTHOR

Name:	Erin M Patrick	
Department:	Wildlife Services	
Institution:	USDA, APHIS, Wildlife Services	
Title:	Wildlife Biologist	
Signature:		Date: 11/20/2018

Please submit a **signed** and **dated** copy of this license by one of the following three methods:

1. Upload an electronic version on the JoVE submission site
2. Fax the document to +1.866.381.2236
3. Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02140



United States Department of Agriculture

Animal and
Plant Health
Inspection
Service

Wildlife Services

4708 Western Ave,
Suite A
Knoxville, TN 37921

(865)588-0299

The authors would like to thank the Review Editor for the specific and helpful editorial comments. We thoughtfully addressed each comment in the amended manuscript that has been uploaded to the JoVE submission site.

Title:

A Protocol for Enhanced Rabies Surveillance Using a Direct Rapid Immunohistochemical Test

Authors:

Erin M Patrick, Brian M Bjorklund, Jordona D Kirby, Kathleen M Nelson, Richard B Chipman, Charles E Rupprecht

The manuscript has been improved according to the suggestions of the Reviewer Editor:

Editorial comments:

1. We thoroughly reviewed the document for spelling and grammar problems.
2. 1.1 edited to imperative tense
3. 1.6 edited to imperative tense
4. Added highlighting of sub-steps for filming.

We hope that our changes and improvements render our manuscript in its current form suitable for publication in JoVE. Again, thanks for taking the time and effort to help us improve this manuscript.

Yours sincerely,

On behalf of the authors,

Erin M. Patrick